Literature DB >> 32365225

Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach?

Maisam Makarem1, Natasha B Leighl1.   

Abstract

Entities:  

Keywords:  NGS; liquid biopsy; lung cancer; molecular testing; plasma cfDNA

Mesh：

Substances：

Year:  2020        PMID： 32365225     DOI： 10.1002/cncr.32875

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  6 in total

Review 1.  Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

2.  Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.

Authors:  Yukti Choudhury; Min-Han Tan; Jun Li Shi; Augustine Tee; Kao Chin Ngeow; Jonathan Poh; Ruth Rosalyn Goh; Jamie Mong
Journal:  Front Med (Lausanne)       Date:  2022-02-11

Review 3.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

Review 4.  Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.

Authors:  Miguel García-Pardo; Maisam Makarem; Janice J N Li; Deirdre Kelly; Natasha B Leighl
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

Review 5.  Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.

Authors:  Diana N Ionescu; Tracy L Stockley; Shantanu Banerji; Christian Couture; Cheryl A Mather; Zhaolin Xu; Normand Blais; Parneet K Cheema; Quincy S-C Chu; Barbara Melosky; Natasha B Leighl
Journal:  Curr Oncol       Date:  2022-07-15       Impact factor: 3.109

6.  Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.

Authors:  Miguel Garcia-Pardo; Kasia Czarnecka; Jennifer H Law; Alexandra Salvarrey; Roxanne Fernandes; Jason Fan; Lucy Corke; Thomas K Waddell; Kazuhiro Yasufuku; Laura L Donahoe; Andrew Pierre; Lisa W Le; Noor Ghumman; Geoffrey Liu; Frances A Shepherd; Penelope Bradbury; Adrian Sacher; Tracy Stockley; Prodipto Pal; Patrik Rogalla; Ming Sound Tsao; Natasha B Leighl
Journal:  Ther Adv Med Oncol       Date:  2022-09-20       Impact factor: 5.485
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.